Keyang Xu

4.9k total citations · 1 hit paper
82 papers, 2.1k citations indexed

About

Keyang Xu is a scholar working on Molecular Biology, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Keyang Xu has authored 82 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Molecular Biology, 26 papers in Radiology, Nuclear Medicine and Imaging and 21 papers in Oncology. Recurrent topics in Keyang Xu's work include Monoclonal and Polyclonal Antibodies Research (23 papers), HER2/EGFR in Cancer Research (18 papers) and Biosimilars and Bioanalytical Methods (13 papers). Keyang Xu is often cited by papers focused on Monoclonal and Polyclonal Antibodies Research (23 papers), HER2/EGFR in Cancer Research (18 papers) and Biosimilars and Bioanalytical Methods (13 papers). Keyang Xu collaborates with scholars based in China, United States and Hong Kong. Keyang Xu's co-authors include Surinder Kaur, Ian A. Blair, Ola M. Saad, Luna Liu, Randall Dere, Alejandro Gutiérrez, Gurkeerat Singh, Montserrat Carrasco‐Triguero, Jagath R. Junutula and Shang‐Fan Yu and has published in prestigious journals such as Nature Communications, ACS Nano and Analytical Chemistry.

In The Last Decade

Keyang Xu

77 papers receiving 1.9k citations

Hit Papers

PEGylated Ultrasmall Iron Oxide Nanoparticles as MRI Cont... 2025 2026 2025 4 8 12
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. PEGylated Ultrasmall Iron Oxide Nanoparticles as MRI Contrast Agents for Vascular Imaging and Real-Time Monitoring
    2025 14 citations Ruru Zhang, Keyang Xu et al. profile →

Peers

Keyang Xu
Maxey C. M. Chung Singapore
David Carlile United Kingdom
Dan A. Rock United States
Amanda F. Baker United States
Dennis Carney Australia
Alessia Lodi United States
Chee M. Ng United States
David R. Light United States
Àngels Sierra Spain
Jean W. Lee United States
Maxey C. M. Chung Singapore
Keyang Xu
Citations per year, relative to Keyang Xu Keyang Xu (= 1×) peers Maxey C. M. Chung

Countries citing papers authored by Keyang Xu

Since Specialization
Citations

This map shows the geographic impact of Keyang Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keyang Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keyang Xu more than expected).

Fields of papers citing papers by Keyang Xu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keyang Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keyang Xu. The network helps show where Keyang Xu may publish in the future.

Co-authorship network of co-authors of Keyang Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Keyang Xu. A scholar is included among the top collaborators of Keyang Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keyang Xu. Keyang Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wang, Ning, et al.. (2025). Glial cell crosstalk in Parkinson's disease: Mechanisms, implications, and therapeutic strategies. Fundamental Research. 5(6). 2960–2974. 6 indexed citations
2.
Xu, Keyang, et al.. (2025). Intranasal delivery of rotigotine to the brain for treating Parkinson’s disease. Fundamental Research. 5(5). 1911–1919.
3.
Yang, Xiaodong, et al.. (2025). Exosomes in Skin Flap Survival: Unlocking Their Role in Angiogenesis and Tissue Regeneration. Biomedicines. 13(2). 353–353. 3 indexed citations
4.
Wang, Heng, Yaling Li, Keyang Xu, et al.. (2025). Global Epidemiology of Early-Onset Aortic Aneurysm: Temporal Trends, Risk Factors, and Future Burden Projections. Journal of Epidemiology and Global Health. 15(1). 25–25. 4 indexed citations
5.
Liu, Cong, et al.. (2025). Roles of the Sec2p Gene in the Growth and Pathogenicity Regulation of Aspergillus fumigatus. Journal of Fungi. 11(1). 36–36. 1 indexed citations
6.
Zheng, Wei, et al.. (2025). Prognostic poteintial of polyamine metabolism-related genes in hepatocellular carcinoma. Scientific Reports. 15(1). 23648–23648.
7.
Xu, Keyang, Jianxian Ge, Xuyi Luo, et al.. (2024). Targeting Ferroptosis in Parkinson’s Disease: Mechanisms and Emerging Therapeutic Strategies. International Journal of Molecular Sciences. 25(23). 13042–13042. 15 indexed citations
8.
Nijem, Ihsan, R. L. Elliott, Jochen Brumm, et al.. (2024). Cross validation of pharmacokinetic bioanalytical methods: Experimental and statistical design. Journal of Pharmaceutical and Biomedical Analysis. 252. 116485–116485. 2 indexed citations
9.
Xu, Keyang, Ai Fu, Tao Su, et al.. (2024). Elevated extracellular matrix protein 1 in circulating extracellular vesicles supports breast cancer progression under obesity conditions. Nature Communications. 15(1). 1685–1685. 10 indexed citations
10.
Wang, Qiang, Henrik Nilsson, Keyang Xu, et al.. (2024). Exploring tumor heterogeneity in colorectal liver metastases by imaging: Unsupervised machine learning of preoperative CT radiomics features for prognostic stratification. European Journal of Radiology. 175. 111459–111459. 8 indexed citations
11.
Fan, Xueying, Mingjing Meng, Hui Chen, et al.. (2023). Brevilin A is a potent anti-metastatic CRC agent that targets the VEGF-IL6-STAT3 axis in the HSCs-CRC interplay. Journal of Translational Medicine. 21(1). 260–260. 12 indexed citations
12.
13.
Zheng, Wei, et al.. (2022). Lnc524369 promotes hepatocellular carcinoma progression and predicts poor survival by activating YWHAZ-RAF1 signaling. World Journal of Gastrointestinal Oncology. 14(1). 253–264. 1 indexed citations
14.
Fourie-O’Donohue, Aimee, Josefa Chuh, Siao Ping Tsai, et al.. (2020). Improved translation of stability for conjugated antibodies using an in vitro whole blood assay. mAbs. 12(1). 1715705–1715705. 8 indexed citations
15.
Chen, Sixiang, et al.. (2020). Role of identified noncoding RNA in erectile dysfunction. Andrologia. 52(7). 8 indexed citations
16.
Liu, Shourong, Xiaoli Hou, Yue Zhang, et al.. (2020). Adipose-tissue derived porcine mesenchymal stem cells efficiently ameliorate CCl4-induced acute liver failure in mice. Cytotechnology. 72(3). 327–341. 2 indexed citations
17.
Xu, Keyang, Shourong Liu, Xu Zhao, et al.. (2018). Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol. Biomedicine & Pharmacotherapy. 110. 844–849. 32 indexed citations
18.
Zhang, Donglu, Shang‐Fan Yu, S. Cyrus Khojasteh, et al.. (2018). Intratumoral Payload Concentration Correlates with the Activity of Antibody–Drug Conjugates. Molecular Cancer Therapeutics. 17(3). 677–685. 31 indexed citations
19.
Xu, Keyang, Luna Liu, Ola M. Saad, et al.. (2011). Characterization of intact antibody–drug conjugates from plasma/serum in vivo by affinity capture capillary liquid chromatography–mass spectrometry. Analytical Biochemistry. 412(1). 56–66. 122 indexed citations
20.
Kouri, Claude El, Seth Force, Michael Y. Chang, et al.. (1999). Use of protamine to augment adenovirus-mediated cancer gene therapy. Gene Therapy. 6(9). 1600–1610. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Maxey C. M. Chung Breakdown of academic impact, for papers by David Carlile Breakdown of academic impact, for papers by Dan A. Rock Breakdown of academic impact, for papers by Amanda F. Baker Breakdown of academic impact, for papers by Dennis Carney Breakdown of academic impact, for papers by Alessia Lodi Breakdown of academic impact, for papers by Chee M. Ng Breakdown of academic impact, for papers by David R. Light Breakdown of academic impact, for papers by Àngels Sierra Breakdown of academic impact, for papers by Jean W. Lee
Rankless by CCL
2026